|
NFKB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.11440000011487E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.51439999999115E-05 |
| Normal-vs-Stage2 |
9.83810000021457E-07 |
| Normal-vs-Stage3 |
2.42129999999952E-05 |
| Normal-vs-Stage4 |
4.22170000002886E-06 |
| Stage1-vs-Stage2 |
4.423600E-02 |
| Stage1-vs-Stage3 |
4.070200E-01 |
| Stage1-vs-Stage4 |
2.594000E-01 |
| Stage2-vs-Stage3 |
2.502600E-01 |
| Stage2-vs-Stage4 |
4.457600E-01 |
| Stage3-vs-Stage4 |
6.929000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.00409999998141E-06 |
| Normal-vs-AfricanAmerican |
4.696700E-03 |
| Normal-vs-Asian |
4.855700E-03 |
| Caucasian-vs-AfricanAmerican |
8.077000E-01 |
| Caucasian-vs-Asian |
4.818800E-01 |
| AfricanAmerican-vs-Asian |
8.002400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.9712000004789E-07 |
| Normal-vs-Female |
1.6934000000024E-06 |
| Male-vs-Female |
2.503000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.450000E-04 |
| Normal-vs-Age(41-60Yrs) |
7.76050000039774E-07 |
| Normal-vs-Age(61-80Yrs) |
4.05810000048135E-08 |
| Normal-vs-Age(81-100Yrs) |
3.287900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.214960E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.184000E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.841200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.723160E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.328400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.565800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.626400E-01 |
| Classical-VS-Follicular |
1.13899999998335E-06 |
| Classical-VS-Other |
2.212200E-01 |
| Classical-VS-Normal |
1.151300E-04 |
| Tall-VS-Follicular |
2.810200E-02 |
| Tall-VS-Other |
4.055600E-01 |
| Tall-VS-Normal |
2.377600E-03 |
| Follicular-VS-Other |
7.271000E-01 |
| Follicular-VS-Normal |
4.88969975620535E-10 |
| Other-VS-Normal |
9.541400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.740200003159E-08 |
| Normal-vs-N1 |
1.86835000000052E-05 |
| N0-vs-N1 |
7.802400E-01 |
|
|
